Anticancer effectiveness of polymeric drug nanocarriers on colorectal cancer cells
Doxifluridine, a prodrug of 5-fluorouracil (5-FU), was used as the initiator directly in ring-opening polymerization of -caprolactone to form hydrophobic doxifluridine-poly(-caprolactone) (doxifluridine-PCL) that was further grafted with hydrophilic chitosan to synthsize amphiphilic doxifluridine-PCL-chitosan copolymer. This amphiphilic copolymer was self-assembled into micellar nanoparticles. After HT-29 colon cancer cells were treated with the polymeric drug nanocarrier, prodrug doxifluridine was converted into 5-fluorouracil by endogenous thymidine phosphorylase (TP) and thereby resulting in cell death. Chemotherapy drug 7-ethyl-10-hydroxy-camptothecin (SN-38), an active water insoluble metabolite of irinoetcan hydrochloride, was further encapsulated in the hydrophobic core of the polymeric drug nanocarriers and treated with HT-29 cells. The anticancer effectiveness of the polymeric drug nanocarriers was extensively enhanced by synergistic anticancer activity of slowly released cytotoxic drugs (i.e., 5-FU and SN-38). HT-29 cells transfected with TP-encoding plasmids were selected by antibiotic G418 to obtain HT-29/TP cells. These cells overexpressed with TP enzyme were challenged with doxifluridine-PCL-chitosan polymeric prodrug micelles. The viability of HT-29/TP cells were dropped significantly after 72-h treatment. © 2011 IEEE.
Proceedings of the Annual International Conference of the IEEE Engineering in Medicine and Biology Society, EMBS
Anticancer effectiveness of polymeric drug nanocarriers on colorectal cancer cells.
Proceedings of the Annual International Conference of the IEEE Engineering in Medicine and Biology Society, EMBS, 3249-3252.
Retrieved from: https://digitalcommons.mtu.edu/michigantech-p/10625